BRPI0417609A - derivados de 3-ciano-quinolina com atividade antiproliferativa - Google Patents

derivados de 3-ciano-quinolina com atividade antiproliferativa

Info

Publication number
BRPI0417609A
BRPI0417609A BRPI0417609-0A BRPI0417609A BRPI0417609A BR PI0417609 A BRPI0417609 A BR PI0417609A BR PI0417609 A BRPI0417609 A BR PI0417609A BR PI0417609 A BRPI0417609 A BR PI0417609A
Authority
BR
Brazil
Prior art keywords
cyano
antiproliferative activity
quinoline derivatives
compounds
formula
Prior art date
Application number
BRPI0417609-0A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Peter Jacobus Johan Buijnsters
Kristof Van Emelen
Werner Constant Joha Embrechts
Timothy Pietro Suren Perera
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0417609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0417609A publication Critical patent/BRPI0417609A/pt
Publication of BRPI0417609B1 publication Critical patent/BRPI0417609B1/pt
Publication of BRPI0417609B8 publication Critical patent/BRPI0417609B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE 3-CIANO-QUINOLINA COM ATIVIDADE ANTIPROLIFERATIVA". A presente invenção diz respeito aos compostos de fórmula (I) as formas N-óxido, os sais de adição farmaceuticamente aceitáveis e as formas estereoquimicamente isoméricas dos mesmos. Compostos de fórmula (I) inibem enzimas tirosina quinase.
BRPI0417609A 2003-12-18 2004-12-15 derivados de 3-ciano-quinolina com atividade antiproliferativa, seu processo de preparação e uso e composição farmacêutica que os compreende BRPI0417609B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51059 2003-12-18
EPPCT/EP03/51059 2003-12-18
PCT/EP2004/053497 WO2005058318A1 (en) 2003-12-18 2004-12-15 3-cyano-quinoline derivatives with antiproliferative activity

Publications (3)

Publication Number Publication Date
BRPI0417609A true BRPI0417609A (pt) 2007-04-10
BRPI0417609B1 BRPI0417609B1 (pt) 2019-02-19
BRPI0417609B8 BRPI0417609B8 (pt) 2021-05-25

Family

ID=34684508

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417609A BRPI0417609B8 (pt) 2003-12-18 2004-12-15 derivados de 3-ciano-quinolina com atividade antiproliferativa, seu processo de preparação e uso e composição farmacêutica que os compreende

Country Status (22)

Country Link
US (4) US7655642B2 (pt)
EP (1) EP1696914B1 (pt)
JP (1) JP4892353B2 (pt)
KR (1) KR101158440B1 (pt)
CN (1) CN1893944B (pt)
AR (1) AR047060A1 (pt)
AT (1) ATE446750T1 (pt)
AU (1) AU2004298784B2 (pt)
BR (1) BRPI0417609B8 (pt)
CA (1) CA2549728C (pt)
DE (1) DE602004023876D1 (pt)
EA (1) EA200601176A1 (pt)
ES (1) ES2335216T3 (pt)
IL (1) IL176358A (pt)
MX (1) MXPA06007018A (pt)
NO (1) NO337622B1 (pt)
NZ (1) NZ547795A (pt)
SG (1) SG151288A1 (pt)
TW (2) TWI389890B (pt)
UA (1) UA83880C2 (pt)
WO (1) WO2005058318A1 (pt)
ZA (1) ZA200604971B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335216T3 (es) 2003-12-18 2010-03-23 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolina con actividad antiproliferativa.
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
EP1951729B1 (en) * 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
EP2044084B1 (en) 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
CA2687909C (en) * 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028613A (en) 1990-02-16 1991-07-02 Repligen Corporation Novel pyrroloquinoline alkaloids and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PL201475B1 (pl) 1998-09-29 2009-04-30 Wyeth Corp Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
KR101064530B1 (ko) * 2002-03-30 2011-09-14 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 티로신 키나아제 억제제로서의 4-(ｎ-페닐아미노)-퀴나졸린/퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
ES2335216T3 (es) * 2003-12-18 2010-03-23 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolina con actividad antiproliferativa.

Also Published As

Publication number Publication date
TWI374879B (en) 2012-10-21
AU2004298784B2 (en) 2011-06-09
US20080139601A1 (en) 2008-06-12
HK1095742A1 (en) 2007-05-18
ZA200604971B (en) 2009-05-27
JP4892353B2 (ja) 2012-03-07
AU2004298784A1 (en) 2005-06-30
WO2005058318A1 (en) 2005-06-30
US9040511B2 (en) 2015-05-26
EP1696914A1 (en) 2006-09-06
US20140256948A1 (en) 2014-09-11
TWI389890B (zh) 2013-03-21
ATE446750T1 (de) 2009-11-15
IL176358A (en) 2010-06-16
US20130197022A1 (en) 2013-08-01
US9365517B2 (en) 2016-06-14
TW200530187A (en) 2005-09-16
JP2007514711A (ja) 2007-06-07
NO20063324L (no) 2006-07-18
DE602004023876D1 (de) 2009-12-10
SG151288A1 (en) 2009-04-30
MXPA06007018A (es) 2006-08-31
US7655642B2 (en) 2010-02-02
CN1893944A (zh) 2007-01-10
UA83880C2 (en) 2008-08-26
CA2549728A1 (en) 2005-06-30
CA2549728C (en) 2015-07-21
TW201132628A (en) 2011-10-01
AR047060A1 (es) 2006-01-04
KR20070005560A (ko) 2007-01-10
IL176358A0 (en) 2006-10-05
ES2335216T3 (es) 2010-03-23
BRPI0417609B1 (pt) 2019-02-19
US8778920B2 (en) 2014-07-15
EP1696914B1 (en) 2009-10-28
BRPI0417609B8 (pt) 2021-05-25
NZ547795A (en) 2009-07-31
KR101158440B1 (ko) 2012-07-06
NO337622B1 (no) 2016-05-09
US20100069424A1 (en) 2010-03-18
CN1893944B (zh) 2011-07-06
EA200601176A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
BRPI0417609A (pt) derivados de 3-ciano-quinolina com atividade antiproliferativa
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
BRPI0507065A (pt) derivados de quinolina e seu uso como inibidores micobacterianos
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
BRPI0515174A (pt) composto ou sais do mesmo, composição farmacêutica, e, uso de um produto farmacêutico
EA200700220A1 (ru) Имидазотриазины в качестве ингибиторов протеинкиназы
SE0202463D0 (sv) Novel compounds
ATE500229T1 (de) Uracilderivate mit herbizider wirkung
NO20026196D0 (no) Kinazolinditosylatsalt forbindelser
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
BR0313407A (pt) Novo uso de derivados de benzotiazol
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
EA200801199A1 (ru) Ингибиторы киназы
MXPA05009282A (es) Derivados de anilina sustituidos.
BRPI0411095A (pt) derivados de imidazol
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
TW200628153A (en) Novel compounds
BRPI0519479A2 (pt) anÁlogos de benzazol 2,5 e 2,6-dissubstituÍdo éteis como inibidores de proteÍna quinase, composiÇço e uso dos mesmos
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
SE0202461D0 (sv) Novel compounds
ATE523498T1 (de) Hiv-inhibierende 2-(4- cyanophenylamino)pyrimidinderivate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.